ArticleDiscover oncology2025
HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards personalized treatment for BCG instillation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comment discusses the findings of a study on the prognostic significance of HER2 expression in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette-Guérin (BCG) therapy. The study highlights that high HER2 expression is an independent predictor of BCG failure and poor recurrence-free survival. The comment underscores the potential of HER2 as a biomarker for tailoring treatment strategies in NMIBC, particularly for patients with high HER2 expression, who may benefit from more aggressive or targeted therapies. It also calls for further validation of HER2-targeted therapies and the need for personalized treatment approaches to improve clinical outcomes in high-risk NMIBC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.